Concepedia

Author

Mark Heise

GlaxoSmithKline (United States)ORCID

Also Known As

M Heise, M. A. Heise, M. Heise, M. Yazawa, Mark A Heise, Mark A. Heise, Mark Heise, Yang X

44

Publications

5K

Citations

19

H-Index

20

Concepts

All Affiliations

GlaxoSmithKline (United States)Harvard UniversityCSL (United States)University of TorontoUniversity of Washington
MH

About

Mark Heise is an author at GlaxoSmithKline (United States) specializing in pharmacology, medicine, and diabetes.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

363

2

Diabetes

3

3

284

3

Health Sciences

2

2

94

4

Emergency Medicine

1

1

79

5

Epidemiology

1

1

79

Mark Heise

×

18

Publications

4.8K

Citations

17

H-Index

YearCitations

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Steven E. Kahn, Steven M. Haffner, Mark Heise,

New England Journal of Medicine

2006

2.9K

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Steven E. Kahn, Bernard Zinman, John M. Lachin,

Diabetes Care

2008

537

A Diabetes Outcome Progression Trial (ADOPT)

Giancarlo Viberti, Steven E. Kahn, Douglas A. Greene,

Diabetes Care

2002

269

Rosiglitazone reduces urinary albumin excretion in type II diabetes

George L. Bakris, Giancarlo Viberti, Wayde M. Weston,

Journal of Human Hypertension

2003

240

Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe

Bernard Zinman, Steven E. Kahn, Steven M. Haffner,

Diabetes

2004

193

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction

C. Michael Gibson, Danielle Duffy, Serge Korjian,

New England Journal of Medicine

2024

102

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

George L. Bakris, Luís M. Ruilope, Stephen McMorn,

Journal of Hypertension

2006

98

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

C. Michael Gibson, John J.P. Kastelein, Adam Phillips,

American Heart Journal

2020

79

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

S. M. A. Bennett, Ajai Agrawal, Hassan Mohamed Saeed Elasha,

Diabetic Medicine

2004

70

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Julio Rosenstock, B. J. Goldstein, A Vinik,

Diabetes Obesity and Metabolism

2005

61

Page 1